JCM
ANIX icon

Jacobi Capital Management’s Anixa Biosciences ANIX Stock Holding History

Jacobi Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,320
Closed -$4K – 717
2016
Q2 		$4K Buy
+1,320
New +$4.02K ﹤0.01% 557

Other funds holding ANIX

BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DIA
Denver Investment Advisors Denver, Colorado $1.89B AUM 7.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jacobi Capital Management's ANIX Position: Q3 2016 in Review

Jacobi Capital Management sold out of Anixa Biosciences (ANIX) in Q3 2016, closing a stake of 1,320 shares — an estimated $4K sold.

Jacobi Capital Management first reported a position in ANIX in Q2 2016 and held it in 1 quarter. The position peaked at $4K in Q2 2016. 13 funds tracked by Wall St. Rank hold ANIX as of Q3 2016.

  • Jacobi Capital Management reported no remaining Anixa Biosciences position as of Q3 2016 after selling out during the quarter.
  • Jacobi Capital Management sold 1,320 Anixa Biosciences shares in Q3 2016, an estimated $4K.
  • Jacobi Capital Management first reported a position in Anixa Biosciences in Q2 2016 and held it in 1 quarter.
  • Jacobi Capital Management's Anixa Biosciences position peaked at $4K in Q2 2016.
  • 13 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2016.

Based on Jacobi Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.